FDA
27th May 2020

How to apply for an FDA Coronavirus Emergency Use Authorization Letter

Applying for a COVID-19 Emergency Use Authorization (EUA) Letter from FDA is no small feat, even though FDA has tried to simplify the process.

How to apply for an FDA Coronavirus Emergency Use Authorization Letter

Applying for a COVID-19 Emergency Use Authorization (EUA) Letter from FDA is no small feat, even though FDA has tried to simplify the process to expedite the availability of diagnostic products, personal protective equipment (PPE), and therapeutics to handle the SARS-CoV-2 pandemic. (You can find FDA’s guidance here.) The upside is a less rigorous regulatory pathway and the ability to market your product prior to receiving full marketing approval. The downside is that the process itself is unfamiliar to most and has been modified more than once since initiation. Furthermore, there are a number of pitfalls or submission package deficiencies that can cause delays and/or rejection of the application.

Common pitfalls include inadequate testing procedures, failure to provide study protocols, presenting topline data only, and incomplete manufacturing data. Fortunately, many of these can be avoided by developing a complete submission package from the onset, rather than engaging in back and forth with FDA regarding deficiencies, which can be time-consuming and delay time to market. For instance, when submitting an EUA package for a serological diagnostic, FDA requires a minimum number of positive and negative samples tested for every matrix (i.e., whole blood, serum, plasma) that the product is intended for. Many applicants only test whole blood but request authorization to market and label the test for all matrices.

The EUA regulatory pathway is not intended as a permanent solution, but rather as a temporary process to address a critical need. Once the EUA process for a particular category expires, all EUAs will become defunct and EUA products removed from the market unless applications have been submitted via the standard (i.e., long and laborious) regulatory pathways. Let ISS assist you in taking advantage of the EUA process now.

ISS has assisted with the submission of dozens of EUA packages, and not just for coronavirus-specific drugs, diagnostics, and devices. We’ve worked directly with FDA on behalf of our clients (as authorized US agents) in order to address deficiencies or revise submissions based on evolving requirements. We know this process inside and out.

Complete the form below to download our free white paper “Applying for an FDA Coronavirus EUA Letter” or contact us today to discuss how we can help.

Download our free white paper “Applying for an FDA Coronavirus EUA Letter”

We have summarized our extensive experience into this easy-to-read, practical guide.

  • Hidden
  • This field is for validation purposes and should be left unchanged.

Recent Related Articles

Best Tips for Medical Device Manufacturers to Write a Compelling Substantial Equivalence Section for their FDA 510k Submission
01 July 2020
Best Tips for Medical Device Manufacturers to Write a Compelling Substantial Equivalence Section for their FDA 510k Submission

Over the past few years, the number of ex-US manufacturers submitting a Class II exempt 510k device registration has increased substantially. For companies with medical devices that are approved and successful in a foreign market, the logical next step is to introduce their product into the US, which has one of the most lucrative healthcare markets in the world. Read more

Evolving FDA Thinking on Advisory Committee Meetings Related to Foods, Drugs, and Devices
25 June 2020
Evolving FDA Thinking on Advisory Committee Meetings Related to Foods, Drugs, and Devices

FDA advisory committee meetings are important regulatory events for many manufacturers on the path to marketing approval. These meetings can quite literally result in the approval or rejection of a product based on the panel’s vote. Read more

NDA vs. OTC Monograph: Which Pathway is Right for You?
22 June 2020
NDA vs. OTC Monograph: Which Pathway is Right for You?

One of the main challenges our clients face is determining which regulatory pathway is best for their products. For example, what if an OTC product has a Monograph active ingredient but that ingredient is present at a different amount than the permitted amount? Or what if the label claims a novel indication not specified in a Monograph? If you are debating pursuit of either regulatory pathway for your OTC drug, it is critical to consider cost, timeline, and label claims to ensure your products has a unique stance in today’s market. Read more

4 Problems Importing Rapid Antibody Tests for Coronavirus
19 June 2020
4 Problems Importing Rapid Antibody Tests for Coronavirus

US distributors and agents trying to import rapid antibody tests for coronavirus face a number of obstacles. The good news is that FDA has opened up the Emergency Use Authorization (EUA) program to include SARS-CoV-2 (the virus) and COVID-19 (the disease), expediting time to market. Read more

Let’s work together

The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us today

Contact us